This site may require a log-in in the near future. We are constantly being swamped by AI agents. If they continue to take down the site, we will be changing to requiring logins to access any item.

🍽️ nifenazone,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Pain Relief: Nifenazone is effective in providing relief from mild to moderate pain associated with various conditions, including musculoskeletal pain, joint pain, dental pain, headaches, menstrual cramps, and postoperative pain. It works by inhibiting the synthesis of prostaglandins, which are substances involved in the transmission of pain signals.

  2. Anti-inflammatory Effects: Similar to other NSAIDs, nifenazone exerts anti-inflammatory effects by inhibiting the activity of cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. By blocking the production of prostaglandins, nifenazone helps reduce inflammation, swelling, and redness at the site of tissue injury or inflammation.

  3. Fever Reduction: Nifenazone possesses antipyretic properties, meaning it can help lower fever by acting on the hypothalamus in the brain, which regulates body temperature. By inhibiting prostaglandin synthesis in the hypothalamus, nifenazone helps bring down elevated body temperature associated with infections or inflammatory conditions.

  4. Musculoskeletal Disorders: Nifenazone is commonly used to manage musculoskeletal disorders such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, gout, tendonitis, and bursitis. By alleviating pain and inflammation in the affected joints, muscles, and connective tissues, nifenazone helps improve mobility and quality of life in individuals with these conditions.

  5. Other Conditions: Nifenazone may also be used to relieve pain and inflammation associated with conditions such as sciatica, neuralgia, sprains, strains, sports injuries, and minor traumas. It is often prescribed as part of a comprehensive treatment plan that may include rest, physical therapy, and other pain management strategies.

  6. Side Effects: While nifenazone can be effective for pain relief and inflammation, it may also cause side effects, particularly when used at high doses or for prolonged periods. Common side effects of nifenazone may include gastrointestinal disturbances such as stomach pain, indigestion, nausea, vomiting, diarrhea, and gastrointestinal ulcers or bleeding. In rare cases, nifenazone may cause allergic reactions, skin rash, dizziness, headache, and liver or kidney problems.

  7. Precautions: Before using nifenazone, individuals should inform their healthcare providers about any preexisting medical conditions, allergies, or medications they are taking, as well as their pregnancy or breastfeeding status. Nifenazone should be used with caution in individuals with a history of gastrointestinal ulcers or bleeding, cardiovascular disease, kidney dysfunction, or liver impairment.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations

βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of nifenazone,(prescription) On Probiotics

Rank Probiotic Impact
species Bacteroides uniformis Reduces
species Escherichia coli Reduces
species Lacticaseibacillus paracasei Reduces
species Parabacteroides distasonis Reduces

Bacteria Impacted by nifenazone,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Escherichia genus Decreases 👪 Source Study
Lacrimispora genus Decreases 👪 Source Study
Lacticaseibacillus genus Decreases 👪 Source Study
Veillonella genus Decreases 👪 Source Study
Bacteroides genus Decreases 👪 Source Study
Parabacteroides genus Decreases 👪 Source Study BMI, fat percent,blood pressure
Mediterraneibacter genus Decreases 👪 Source Study
Thomasclavelia genus Decreases 👪 Source Study
Streptococcus genus Decreases 👪 Source Study
Roseburia genus Decreases 👪 Source Study
Dorea genus Decreases 👪 Source Study
Fusobacterium genus Decreases 👪 Source Study Periodontal disease, Lemierre syndrome, skin ulcers
Odoribacter genus Decreases 👪 Source Study
Escherichia coli O1:K1:H7 no rank Decreases 👶 Source Study
Escherichia coli O139:H1 no rank Decreases 👶 Source Study
Escherichia coli O141:H4 no rank Decreases 👶 Source Study
Escherichia coli O145:H34 no rank Decreases 👶 Source Study
Escherichia coli O15:H12 no rank Decreases 👶 Source Study
Escherichia coli O155:H21 no rank Decreases 👶 Source Study
Escherichia coli O158:H23 no rank Decreases 👶 Source Study
Escherichia coli O16:H48 no rank Decreases 👶 Source Study
Escherichia coli O170:H18 no rank Decreases 👶 Source Study
Escherichia coli O18ac:H14 no rank Decreases 👶 Source Study
Escherichia coli O19:H7 no rank Decreases 👶 Source Study
Escherichia coli O2:K1:H4 no rank Decreases 👶 Source Study
Escherichia coli O2:K1:H5 no rank Decreases 👶 Source Study
Escherichia coli O2:K1:H7 no rank Decreases 👶 Source Study
Escherichia coli O20:H12 no rank Decreases 👶 Source Study
Escherichia coli O25:H16 no rank Decreases 👶 Source Study
Escherichia coli O55:H7 no rank Decreases 👶 Source Study
Escherichia coli O68:H12 no rank Decreases 👶 Source Study
Escherichia coli O7:H15 no rank Decreases 👶 Source Study
Escherichia coli O78:H51 no rank Decreases 👶 Source Study
Escherichia coli O80:H26 no rank Decreases 👶 Source Study
Escherichia coli O84:H7 no rank Decreases 👶 Source Study
Escherichia coli O85:H1 no rank Decreases 👶 Source Study
Escherichia coli O121 serogroup Decreases 👶 Source Study
Escherichia coli O145 serogroup Decreases 👶 Source Study
Escherichia coli O155 serogroup Decreases 👶 Source Study
Escherichia coli O157 serogroup Decreases 👶 Source Study
Escherichia coli O177 serogroup Decreases 👶 Source Study
Escherichia coli O26 serogroup Decreases 👶 Source Study
Escherichia coli O3 serogroup Decreases 👶 Source Study
Escherichia coli O43 serogroup Decreases 👶 Source Study
Escherichia coli O78 serogroup Decreases 👶 Source Study
Escherichia coli O86 serogroup Decreases 👶 Source Study
Escherichia coli O91 serogroup Decreases 👶 Source Study
Escherichia coli H20 serotype Decreases 👶 Source Study
Escherichia coli O1:H42 serotype Decreases 👶 Source Study
Escherichia coli O1:HNT serotype Decreases 👶 Source Study
Escherichia coli O10:H32 serotype Decreases 👶 Source Study
Escherichia coli O100:H21 serotype Decreases 👶 Source Study
Escherichia coli O103:H2 serotype Decreases 👶 Source Study
Escherichia coli O104:H4 serotype Decreases 👶 Source Study
Escherichia coli O111:H- serotype Decreases 👶 Source Study
Escherichia coli O111:H8 serotype Decreases 👶 Source Study
Escherichia coli O111:NM serotype Decreases 👶 Source Study
Escherichia coli O112ab:H8 serotype Decreases 👶 Source Study
Escherichia coli O112ac:H19 serotype Decreases 👶 Source Study
Escherichia coli O113:H21 serotype Decreases 👶 Source Study
Escherichia coli O114:H49 serotype Decreases 👶 Source Study
Escherichia coli O121:H19 serotype Decreases 👶 Source Study
Escherichia coli O125ac:K+:H10 serotype Decreases 👶 Source Study
Escherichia coli O126:H45 serotype Decreases 👶 Source Study
Escherichia coli O127:H6 serotype Decreases 👶 Source Study
Escherichia coli O128ac:H12 serotype Decreases 👶 Source Study
Escherichia coli O139:H28 serotype Decreases 👶 Source Study
Escherichia coli O145:H25 serotype Decreases 👶 Source Study
Escherichia coli O145:H28 serotype Decreases 👶 Source Study
Escherichia coli O145:NM serotype Decreases 👶 Source Study
Escherichia coli O15:H18 serotype Decreases 👶 Source Study
Escherichia coli O150:H6 serotype Decreases 👶 Source Study
Escherichia coli O152:H23 serotype Decreases 👶 Source Study
Escherichia coli O157:H- serotype Decreases 👶 Source Study
Escherichia coli O157:H43 serotype Decreases 👶 Source Study
Escherichia coli O157:H7 serotype Decreases 👶 Source Study bloody diarrhea
Escherichia coli O16:H6 serotype Decreases 👶 Source Study
Escherichia coli O167:H26 serotype Decreases 👶 Source Study
Escherichia coli O174:H21 serotype Decreases 👶 Source Study
Escherichia coli O176:H45 serotype Decreases 👶 Source Study
Escherichia coli O2:H6 serotype Decreases 👶 Source Study
Escherichia coli O2:K2:H1 serotype Decreases 👶 Source Study
Escherichia coli O25:H1 serotype Decreases 👶 Source Study
Escherichia coli O25:NM serotype Decreases 👶 Source Study
Escherichia coli O26:H11 serotype Decreases 👶 Source Study
Escherichia coli O44:H18 serotype Decreases 👶 Source Study
Escherichia coli O45:H2 serotype Decreases 👶 Source Study
Escherichia coli O6:H16 serotype Decreases 👶 Source Study
Escherichia coli O6:K2:H1 serotype Decreases 👶 Source Study
Escherichia coli O7:H4 serotype Decreases 👶 Source Study
Escherichia coli O7:K1 serotype Decreases 👶 Source Study
Escherichia coli O78:H4 serotype Decreases 👶 Source Study
Escherichia coli O8:H8 serotype Decreases 👶 Source Study
Escherichia coli O89m:H10 serotype Decreases 👶 Source Study
Escherichia coli O89m:H9 serotype Decreases 👶 Source Study
Escherichia coli O9:H10 serotype Decreases 👶 Source Study
Escherichia coli O99:H6 serotype Decreases 👶 Source Study
Escherichia coli species Decreases 📓 Source Study Diarrheal disease in children and travelers, Foodborne diarrhea outbreaks, hemorrhagic colitis, hemolytic-uremic syndrome
Lacrimispora saccharolytica species Decreases 📓 Source Study
Bacteroides xylanisolvens species Decreases 📓 Source Study
Lacticaseibacillus paracasei species Decreases 📓 Source Study
Veillonella parvula species Decreases 📓 Source Study
Bacteroides fragilis species Decreases 📓 Source Study H02076 Bacteroides infection
Parabacteroides distasonis species Decreases 📓 Source Study
Parabacteroides merdae species Decreases 📓 Source Study Infectious bacteria
[Ruminococcus] torques species Decreases 📓 Source Study
Thomasclavelia ramosa species Decreases 📓 Source Study
Streptococcus salivarius species Decreases 📓 Source Study Infectious bacteria
Roseburia hominis species Decreases 📓 Source Study
Bacteroides uniformis species Decreases 📓 Source Study Infectious bacteria
Dorea formicigenerans species Decreases 📓 Source Study
Fusobacterium nucleatum species Decreases 📓 Source Study Infectious bacteria
Odoribacter splanchnicus species Decreases 📓 Source Study
Lacticaseibacillus paracasei subsp. paracasei subspecies Decreases 👶 Source Study
Lacticaseibacillus paracasei subsp. tolerans subspecies Decreases 👶 Source Study
Fusobacterium nucleatum subsp. nucleatum subspecies Decreases 👶 Source Study

Impact of nifenazone,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
ADHD 0.4 0.4
Age-Related Macular Degeneration and Glaucoma 0.1 0.1 0
Allergic Rhinitis (Hay Fever) 0.7 0.7
Allergies 1.1 1.1
Allergy to milk products 0.9 0.5 0.8
Alopecia (Hair Loss) 0.3 0.3
Alzheimer's disease 1.1 1.3 -0.18
Amyotrophic lateral sclerosis (ALS) Motor Neuron 0.8 0.7 0.14
Ankylosing spondylitis 1.8 0.2 8
Anorexia Nervosa 0.1 0.3 -2
Antiphospholipid syndrome (APS) 0.8 0.8
Asthma 0.3 -0.3
Atherosclerosis 0 0.1 0
Atrial fibrillation 0.7 0.7 0
Autism 1.4 1.5 -0.07
Barrett esophagus cancer 0.3 0.1 2
benign prostatic hyperplasia 0.4 0.4
Biofilm 0.8 0.8
Bipolar Disorder 0.7 0.3 1.33
Brain Trauma 0.3 -0.3
Cancer (General) 0 0.5 0
Carcinoma 0.8 0.4 1
Celiac Disease 1.3 0.6 1.17
Cerebral Palsy 0.3 0.3 0
Chronic Fatigue Syndrome 1.6 1.2 0.33
Chronic Kidney Disease 0.9 0.1 8
Chronic Lyme 0.3 -0.3
Chronic Obstructive Pulmonary Disease (COPD) 0.6 0.1 5
Chronic Urticaria (Hives) 1.4 0.4 2.5
Coagulation / Micro clot triggering bacteria 1.3 0.2 5.5
Colorectal Cancer 2.2 2.2
Constipation 0.5 0.1 4
Coronary artery disease 0.2 -0.2
COVID-19 2.4 1.1 1.18
Crohn's Disease 2.3 0.8 1.87
cystic fibrosis 1.1 0.3 2.67
deep vein thrombosis 1.1 0.2 4.5
Depression 2.2 1.9 0.16
Dermatomyositis 0.1 0.1
Eczema 0.6 0.7 -0.17
Endometriosis 1.5 0.3 4
Eosinophilic Esophagitis 0 0.2 0
Epilepsy 1 0.6 0.67
Fibromyalgia 0.8 0.3 1.67
Functional constipation / chronic idiopathic constipation 1.7 0.9 0.89
gallstone disease (gsd) 0.8 0.1 7
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 0.6 0.1 5
Generalized anxiety disorder 1.1 0.2 4.5
Glioblastoma 0.1 -0.1
Graves' disease 0.3 0.1 2
Halitosis 0.4 0.1 3
Hashimoto's thyroiditis 0.5 0.2 1.5
Hidradenitis Suppurativa 0.1 0.2 -1
High Histamine/low DAO 0.8 0.8
hypercholesterolemia (High Cholesterol) 0 0
hyperglycemia 0.4 0.3 0.33
hypertension (High Blood Pressure 0.8 1 -0.25
Hypoxia 0.3 0.3
IgA nephropathy (IgAN) 0.1 -0.1
Inflammatory Bowel Disease 2.2 0.9 1.44
Insomnia 0.3 0.3 0
Intelligence 0.1 0.1
Intracranial aneurysms 0.3 0.3
Irritable Bowel Syndrome 1.6 0.8 1
Liver Cirrhosis 1.2 0.6 1
Long COVID 1.3 0.5 1.6
Low bone mineral density 0.1 -0.1
Lung Cancer 0.4 0 0
Mast Cell Issues / mastitis 0.5 0.5
ME/CFS with IBS 0.1 0.2 -1
ME/CFS without IBS 0.1 0.6 -5
Metabolic Syndrome 2 1.3 0.54
Mood Disorders 2.7 1.9 0.42
multiple chemical sensitivity [MCS] 0.6 0.6
Multiple Sclerosis 0.5 1.2 -1.4
Multiple system atrophy (MSA) 0.2 0.2
neuropathic pain 0.4 -0.4
Neuropathy (all types) 0.1 0.4 -3
neuropsychiatric disorders (PANDAS, PANS) 0.7 0.7
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 0.5 0.2 1.5
NonCeliac Gluten Sensitivity 0.2 -0.2
Obesity 1.5 1.1 0.36
obsessive-compulsive disorder 2.2 0.4 4.5
Osteoarthritis 0.9 0.9
Osteoporosis 0.8 0.2 3
pancreatic cancer 0.1 0.1
Parkinson's Disease 2.1 2.1 0
Polycystic ovary syndrome 0.7 0.1 6
Premenstrual dysphoric disorder 0.1 -0.1
primary biliary cholangitis 0 0.1 0
Psoriasis 1.5 0.7 1.14
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 1 0.9 0.11
Rosacea 0.2 0.1 1
Schizophrenia 0.9 0.1 8
Sjögren syndrome 1.3 0.4 2.25
Sleep Apnea 0 0.3 0
Slow gastric motility / Gastroparesis 1.1 1.1
Small Intestinal Bacterial Overgrowth (SIBO) 0.9 0.9
Stress / posttraumatic stress disorder 1.2 0.3 3
Systemic Lupus Erythematosus 1.4 0.1 13
Tic Disorder 0 0 0
Tourette syndrome 0.2 -0.2
Type 1 Diabetes 1.1 0.2 4.5
Type 2 Diabetes 2 1.8 0.11
Ulcerative colitis 1.6 0.5 2.2
Unhealthy Ageing 1.2 0.1 11
Vitiligo 0.5 0.1 4

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.

Copyright 2016 - 2024 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.
Inventions /Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [34.204.176 ]

Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [34.204.176 ]